Baer D M, Paulson R A
Ther Drug Monit. 1987;9(1):72-7. doi: 10.1097/00007691-198703000-00013.
Hyperlipidemia interferes with spectrophotometric assays of a number of analytes. No interference was found in the assay of gentamicin, phenytoin, or phenobarbital due to turbidity in levels of triglyceride less than or equal to 2,000 mg/dl with the Abbott TDx or Syva enzyme multiplied immunoassay (EMIT) methods. There is no evidence that lipophilic drugs partition into the lipid phase in severely hyperlipidemic serum. No assay errors due to turbidity or partitioning of phenobarbital in the lipid of serum with a triglyceride concentration of 10,000 mg/dl were found, nor were changes seen in free phenytoin distribution due to hyperlipidemia.
高脂血症会干扰多种分析物的分光光度测定。使用雅培TDx或西瓦酶放大免疫分析（EMIT）方法时，甘油三酯水平小于或等于2000mg/dl时，未发现庆大霉素、苯妥英或苯巴比妥的测定因浊度而受到干扰。没有证据表明亲脂性药物会在严重高脂血症血清中分配到脂质相中。在甘油三酯浓度为10000mg/dl的血清中，未发现苯巴比妥因浊度或脂质分配导致的测定误差，也未发现高脂血症导致游离苯妥英分布发生变化。
